UK: A secondary analysis of the FINEARTS-HF randomized clinical trial evaluated the performance of the PREDICT-HFpEF model in ...

The multicenter trial will enroll over 1,000 patients across 24 medical centers in Spain to confirm whether ReDS-guided heart failure (HF) management improves 30-day patient outcomes compared to ...

In the METEORIC-HF trial, omecamtiv was unable to show an improved performance in exercise capacity among patients with heart failure with reduced ejection fraction (HFrEF) compared to placebo.

The ALLAY-HFrEF trial will support the company’s first pivotal trial, ALLAY-HF (NCT05685303), which is ... We welcome Gilde Healthcare and Omega to this strong partnership.” ...

We investigated the non-steroidal MRA, finerenone, in patients with HFmrEF/HFpEF in the FINEARTS-HF trial, and a significant positive impact on outcomes was observed." FINEARTS-HF was a double ...

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.

that can enhance uptake of guideline-directed medical therapy (GDMT), the AIM-POWER trial shows. Compared with usual care, use of the BiovitalsHF platform (Biofourmis) provided a greater increase in ...

Summary of key findings: The DELTA-HF feasibility study is continuing to enroll patients in Europe. A randomized controlled trial will begin in the United States, Canada and Europe later this year.

BioCardia (BCDA) announced completion of source data verification and freezing of primary outcomes data in the double-blind randomized ...

BOSTON, Feb. 24, 2025 /PRNewswire/ -- At the THT conference, Dr. Jesus Alvarez-Garcia, MD, PhD, head of Advanced Heart Failure Unit at Ramón y Cajal Hospital in Madrid, announced the launch of ...